Skip to main content
Clinical Trials/NCT06463249
NCT06463249
Recruiting
Not Applicable

Scaling up Behavioral Weight Loss Opportunities for Cancer Survivors With Overweight or Obesity in Maryland: A Randomized Trial With Adaptive Interventions (Helpline for Weight Loss)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1 site in 1 country200 target enrollmentJune 17, 2024
ConditionsWeight Loss

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Weight Loss
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enrollment
200
Locations
1
Primary Endpoint
Weight (pounds) changes at 8 months from 2-month between Enhanced Helpline and Intensive Helpline arms
Status
Recruiting
Last Updated
9 months ago

Overview

Brief Summary

The objective of the HELPLINE Weight Loss Program is to determine the comparative effectiveness of two active multi-component, augmented interventions for cancer survivors with overweight or obesity who do not achieve early weight loss goal in the initial intervention period (termed, early non-responders). The core study design is randomized controlled trial with adaptive intervention.

  1. CORE Helpline in all participants (first 2 months)
  2. Extended Helpline in early responders (additional 6 months)
  3. Enhanced Helpline in early non-responders (additional 6 months)
  4. Intensive Helpline in early non-responders (additional 6 months)

Detailed Description

All participants will receive * written Johns Hopkins weight loss material * instructions for using a smartphone weight loss app to keep track of food and exercise every day (either android or iPhone) * a weekly weight loss tip by text message and email, and a text message on weight loss progress each week * a research scale and specific instructions for verifying weights at 5 specific times over the next year. The participants may also request two 20-minute phone calls during the first 2 months with a weight loss coach. After the first 2 months, depending on weight loss progress, the participants will be assigned to another program which may include additional assistance for 6 more months. Additional assistance may include scheduled phone calls with a Johns Hopkins weight loss coach each month, individualized emails from a Johns Hopkins weight loss coach, and the option for daily text message reminders. After the first 8 months of assistance, the participants will continue the program on the participant's own for 4 more months and provide the study team with final weights 12 months after the start of the program.

Registry
clinicaltrials.gov
Start Date
June 17, 2024
End Date
December 1, 2027
Last Updated
9 months ago
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Women and men ages 18 or older
  • Able to complete all study requirements in English
  • Have been previously diagnosed with a malignant solid tumor, completed the required surgical, and/or chemotherapy and/or radiation curative intent therapy at least three months prior to enrollment, and have an anticipated treatment-free life span of 12 months or longer. Chemoprophylaxis with tamoxifen or aromatase inhibitors for breast cancer in women and anti- luteinizing hormone-releasing hormone (LHRH) therapy for prostate cancer in men will be permitted.
  • Have a BMI ≥ 27 kg/m2 (BMI ≥ 25 kg/m2 for Asians) and weight ≤ 400 lbs.
  • Have an email address for regular personal use
  • Have a smartphone for personal use, and are willing to use the phone to read emails and text messages, and use an app
  • Have adequate data plan and cell service to support daily use of weight loss app, receive text messages and to support coaching calls
  • Are willing to record weekly weights
  • Are willing to use a tracking app to log food and exercise daily
  • Are willing to complete coaching calls as planned

Exclusion Criteria

  • Received any chemotherapy (unless anti-hormonal therapy) and/or radiation three months or less prior to the proposed program date
  • Women who are breastfeeding, pregnant, or planning pregnancy within the next year
  • self-identification of uncontrolled concurrent medical condition likely to limit compliance with the program as determined by investigators.
  • current involvement in another organized weight loss program
  • current use of medications known to substantially affect body weight, including chronic oral steroids, Tirzepatide (Mounjaro™), and weight loss doses of other glucagon-like peptide 1 (GLP-1) agonists (e.g. Wegovy.)
  • bariatric surgery scheduled within the next 12 months
  • plan to move outside the continental United States in the next 12 months
  • Weight loss or gain of \>5.0% of body weight during 2 months prior to screening

Outcomes

Primary Outcomes

Weight (pounds) changes at 8 months from 2-month between Enhanced Helpline and Intensive Helpline arms

Time Frame: 8 months

Weight change for Enhanced Helpline and Intensive Helpline in early non-responders

Secondary Outcomes

  • Weight (pounds) change at 5 and 12 months from 2-month between Enhanced Helpline and Intensive Helpline arms(12 months)

Study Sites (1)

Loading locations...

Similar Trials